Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine

BIOLOGICAL2 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

Healthy VolunteersMeningococcal ImmunisationMeningococcal Immunisation (Healthy Volunteers)

Phase 1

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

TerminatedNCT04825223

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers, Meningococcal Immunisation

Start: 2021-03-29End: 2022-07-22Updated: 2025-10-10

Phase 3

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

CompletedNCT04084769

Sanofi Pasteur, a Sanofi CompanyMeningococcal Immunisation (Healthy Volunteers)

Start: 2019-09-03End: 2020-09-14Updated: 2025-09-15

Related Papers

Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study

Pediatric Research2023-03-1011 citations

03. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster Dose in Adults and Adolescents Vaccinated Against Meningococcal Disease 3 - 6 Years Earlier

Open Forum Infectious Diseases2021-11-012 citations